

# Uwe Siebert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/682044/publications.pdf>

Version: 2024-02-01

351  
papers

20,733  
citations

14124

69  
h-index

13635

134  
g-index

381  
all docs

381  
docs citations

381  
times ranked

25355  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2009, 360, 213-224.	13.9	3,510
2	Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 177-184.	1.2	990
3	Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. <i>The Cochrane Library</i> , 2020, 4, CD013574.	1.5	571
4	The Effect of Electronic Prescribing on Medication Errors and Adverse Drug Events: A Systematic Review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2008, 15, 585-600.	2.2	537
5	Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. <i>Value in Health</i> , 2012, 15, 796-803.	0.1	481
6	Prevalence and incidence of Parkinson's disease in Europe. <i>European Neuropsychopharmacology</i> , 2005, 15, 473-490.	0.3	461
7	Modeling Good Research Practices—Overview. <i>Medical Decision Making</i> , 2012, 32, 667-677.	1.2	389
8	Key principles for the improved conduct of health technology assessments for resource allocation decisions. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 244-258.	0.2	356
9	State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. <i>Value in Health</i> , 2012, 15, 812-820.	0.1	336
10	Economic Evaluation of Fractional Flow Reserve—Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease. <i>Circulation</i> , 2010, 122, 2545-2550.	1.6	332
11	Economic burden of stroke: a systematic review on post-stroke care. <i>European Journal of Health Economics</i> , 2019, 20, 107-134.	1.4	300
12	Coronary Pressure Measurement After Stenting Predicts Adverse Events at Follow-Up. <i>Circulation</i> , 2002, 105, 2950-2954.	1.6	293
13	Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. <i>Value in Health</i> , 2009, 12, 1052-1061.	0.1	246
14	Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. <i>Value in Health</i> , 2009, 12, 1062-1073.	0.1	234
15	Long-Term Outcome After Stroke. <i>Stroke</i> , 2006, 37, 193-198.	1.0	233
16	State-Transition Modeling. <i>Medical Decision Making</i> , 2012, 32, 690-700.	1.2	231
17	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	2.2	205
18	Resistance Training in the Treatment of the Metabolic Syndrome. <i>Sports Medicine</i> , 2010, 40, 397-415.	3.1	191

#	ARTICLE	IF	CITATIONS
19	HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. <i>BMC Public Health</i> , 2009, 9, 34.	1.2	188
20	Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. <i>Gut</i> , 2003, 52, 425-432.	6.1	180
21	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	3.8	180
22	Mercury as a serious health hazard for children in gold mining areas. <i>Environmental Research</i> , 2008, 107, 89-97.	3.7	175
23	Diagnostic and Prognostic Value of Serial Dobutamine Stress Echocardiography for Noninvasive Assessment of Cardiac Allograft Vasculopathy. <i>Circulation</i> , 1999, 100, 509-515.	1.6	173
24	Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1079-1084.	0.5	169
25	Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. <i>The Cochrane Library</i> , 2020, 2020, CD013574.	1.5	168
26	Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve. <i>European Heart Journal</i> , 2006, 27, 1465-1471.	1.0	163
27	Fractional Flow Reserve in Unstable Angina and Non-“ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1183-1189.	1.1	158
28	A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. <i>European Journal of Radiology</i> , 2008, 65, 449-461.	1.2	156
29	A Systematic Meta-Analysis of the Efficacy and Heterogeneity of Disease Management Programs in Congestive Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, 554-567.	0.7	151
30	Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes. <i>Epilepsia</i> , 2019, 60, 53-62.	2.6	151
31	EBM, HTA, and CER: Clearing the Confusion. <i>Milbank Quarterly</i> , 2010, 88, 256-276.	2.1	140
32	When should decision-analytic modeling be used in the economic evaluation of health care?. <i>European Journal of Health Economics</i> , 2003, 4, 143-150.	1.4	139
33	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. <i>Value in Health</i> , 2008, 11, 539-544.	0.1	138
34	Health-related quality of life in patients with narcolepsy. <i>Sleep Medicine</i> , 2007, 8, 733-741.	0.8	134
35	Rate of clinical progression in Parkinson's disease. A prospective study. <i>Movement Disorders</i> , 2007, 22, 938-945.	2.2	129
36	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	12.5	129

#	ARTICLE	IF	CITATIONS
37	Cost of Illness and its Predictors for Parkinson's Disease in Germany. <i>Pharmacoeconomics</i> , 2005, 23, 817-836.	1.7	125
38	Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. <i>Value in Health</i> , 2012, 15, 1162-1171.	0.1	119
39	Health assessment of artisanal gold miners in Indonesia. <i>Science of the Total Environment</i> , 2010, 408, 713-725.	3.9	111
40	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	0.6	107
41	Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. <i>Aids</i> , 2003, 17, 1521-1529.	1.0	105
42	Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort—Consequences for progression studies. <i>European Journal of Radiology</i> , 2006, 57, 396-402.	1.2	103
43	Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1781-1788.	1.2	102
44	Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. <i>Journal of Hepatology</i> , 2007, 47, 270-276.	1.8	100
45	Diagnostic Performance of Stress Perfusion and Delayed-Enhancement MR Imaging in Patients with Coronary Artery Disease. <i>Radiology</i> , 2006, 240, 39-45.	3.6	99
46	Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve?. <i>American Heart Journal</i> , 2004, 148, 590-595.	1.2	98
47	Utility Estimates for Decision-Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations. <i>Value in Health</i> , 2009, 12, 185-187.	0.1	98
48	The efficiency frontier approach to economic evaluation of health-care interventions. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1117-1127.	0.8	97
49	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. <i>Pharmacoeconomics</i> , 2016, 34, 227-244.	1.7	97
50	Critical Limb Ischemia: Hybrid MR Angiography Compared with DSA. <i>Radiology</i> , 2005, 235, 308-318.	3.6	94
51	Systematic overview of cost-effectiveness thresholds in ten countries across four continents. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 485-504.	0.6	92
52	Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: A meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 314-321.	0.7	90
53	Long-Term Patency of Internal Mammary Artery Bypass Grafts: Relationship With Preoperative Severity of the Native Coronary Artery Stenosis. <i>Circulation</i> , 2004, 110, II-36-II-40.	1.6	90
54	High-resolution MR Imaging of Human Atherosclerotic Femoral Arteries In Vivo: Validation with Intravascular Ultrasound. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, 227-231.	0.2	89

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness of Using N-Terminal Pro-Brain Natriuretic Peptide to Guide the Diagnostic Assessment and Management of Dyspneic Patients in the Emergency Department. <i>American Journal of Cardiology</i> , 2006, 98, 800-805.	0.7	88
56	Resistance training, visceral obesity and inflammatory response: a review of the evidence. <i>Obesity Reviews</i> , 2012, 13, 578-591.	3.1	87
57	Costs of illness and care in Parkinson's Disease: An evaluation in six countries. <i>European Neuropsychopharmacology</i> , 2011, 21, 180-191.	0.3	84
58	Market uptake of new antiviral drugs for the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2008, 49, 528-536.	1.8	83
59	BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. <i>European Journal of Epidemiology</i> , 2014, 29, 777-790.	2.5	83
60	Progression-free survival as a surrogate endpoint in advanced breast cancer. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 371-383.	0.2	82
61	Health assessment of artisanal gold miners in Tanzania. <i>Science of the Total Environment</i> , 2010, 408, 796-805.	3.9	81
62	Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. <i>Journal of Personalized Medicine</i> , 2015, 5, 470-486.	1.1	81
63	Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 763-771.	2.2	79
64	Rationale and design of the fractional flow reserve versus angiography for multivessel evaluation (FAME) study. <i>American Heart Journal</i> , 2007, 154, 632-636.	1.2	78
65	The Socioeconomic Impact of Narcolepsy. <i>Sleep</i> , 2004, 27, 1123-1128.	0.6	77
66	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. <i>Value in Health</i> , 2019, 22, 13-20.	0.1	76
67	Decision-Analytic Modeling to Evaluate Benefits and Harms of Medical Tests: Uses and Limitations. <i>Medical Decision Making</i> , 2009, 29, E22-E29.	1.2	73
68	The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. <i>Transplantation</i> , 2002, 73, 547-552.	0.5	71
69	Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. <i>Annals of Oncology</i> , 2004, 15, 863-869.	0.6	71
70	Cost-effectiveness Analysis in the Assessment of Diagnostic Imaging Technologies. <i>Radiology</i> , 2005, 235, 361-370.	3.6	71
71	Gender differences in the association between grip strength and mortality in older adults: results from the KORA-age study. <i>BMC Geriatrics</i> , 2016, 16, 201.	1.1	70
72	A preliminary study on health effects in villagers exposed to mercury in a small-scale artisanal gold mining area in Indonesia. <i>Environmental Research</i> , 2016, 149, 274-281.	3.7	70

#	ARTICLE	IF	CITATIONS
73	Mercury in breast milk – A health hazard for infants in gold mining areas?. International Journal of Hygiene and Environmental Health, 2008, 211, 615-623.	2.1	68
74	Resource Utilization and Costs of Stroke Unit Care in Germany. Value in Health, 2004, 7, 144-152.	0.1	67
75	PREVENTION OF OSTEOPOROSIS AFTER CARDIAC TRANSPLANTATION. Transplantation, 1999, 68, 523-530.	0.5	67
76	A validated clinical and biochemical score for the diagnosis of acute heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. American Heart Journal, 2006, 151, 48-54.	1.2	63
77	Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncologist, 2010, 15, 1179-1191.	1.9	63
78	Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011. PLoS ONE, 2016, 11, e0153106.	1.1	63
79	The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany. European Journal of Public Health, 2006, 16, 185-192.	0.1	62
80	Demonstration of the healthy worker survivor effect in a cohort of workers in the construction industry. Occupational and Environmental Medicine, 2001, 58, 774-779.	1.3	61
81	Cost of Parkinson's disease in Europe. European Journal of Neurology, 2005, 12, 68-73.	1.7	60
82	Concepts of –Personalization–™ in Personalized Medicine: Implications for Economic Evaluation. Pharmacoeconomics, 2015, 33, 49-59.	1.7	59
83	Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value in Health, 2020, 23, 529-539.	0.1	59
84	Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients ? The IMPROVED multi-centre study. European Heart Journal, 2004, 25, 1626-1634.	1.0	56
85	The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment, 2006, 10, iii-iv, ix-xii, 1-93.	1.3	56
86	Cardiac CT in Emergency Department Patients with Acute Chest Pain. Radiographics, 2006, 26, 963-978.	1.4	55
87	Development and evaluation of the Parkinson Psychosis Questionnaire. Journal of Neurology, 2005, 252, 1060-1066.	1.8	53
88	Intravascular Optical Coherence Tomography: Comparison with Histopathology in Atherosclerotic Peripheral Artery Specimens. Journal of Vascular and Interventional Radiology, 2006, 17, 343-349.	0.2	52
89	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. International Journal of Technology Assessment in Health Care, 2010, 26, 71-78.	0.2	52
90	Mercury exposure in female artisanal small-scale gold miners (ASGM) in Mongolia: An analysis of human biomonitoring (HBM) data from 2008. Science of the Total Environment, 2011, 409, 994-1000.	3.9	52

#	ARTICLE	IF	CITATIONS
91	Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons. <i>PLoS ONE</i> , 2013, 8, e82967.	1.1	51
92	Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection. <i>European Journal of Public Health</i> , 2009, 19, 245-253.	0.1	49
93	Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. <i>Vaccine</i> , 2009, 27, 5133-5141.	1.7	49
94	Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 847-855.	0.9	49
95	The burden of chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe: data availability and preliminary estimates. <i>Environmental Health</i> , 2014, 13, 111.	1.7	48
96	Superiority of age and weight as variables in predicting osteoporosis in postmenopausal white women. <i>Osteoporosis International</i> , 2003, 14, 950-956.	1.3	45
97	Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 305-314.	0.2	44
98	Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery*. <i>Critical Care Medicine</i> , 2004, 32, 1866-1871.	0.4	41
99	Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis. <i>Heart</i> , 2005, 91, 203-206.	1.2	41
100	Cost effectiveness of haemophilia treatment: a cross-national assessment. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 477-485.	0.5	40
101	Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. <i>International Angiology</i> , 2002, 21, 305-15.	0.4	40
102	A network against failing heartsâ€”Introducing the German â€œCompetence Network Heart Failureâ€•. <i>International Journal of Cardiology</i> , 2010, 145, 135-138.	0.8	39
103	Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. <i>International Journal of Public Health</i> , 2012, 57, 57-62.	1.0	39
104	Costâ€•effectiveness of neurostimulation in Parkinson's disease with early motor complications. <i>Movement Disorders</i> , 2016, 31, 1183-1191.	2.2	39
105	Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security. <i>International Journal of Technology Assessment in Health Care</i> . 2005, 21, 55-65.	0.2	38
106	Signs and symptoms of mercury-exposed gold miners. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2017, 30, 249-269.	0.6	38
107	Health technology assessment of medical devices: What is different? An overview of three European projects. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2015, 109, 309-318.	0.7	37
108	Personalized medicine in Europe: not yet personal enough?. <i>BMC Health Services Research</i> , 2017, 17, 289.	0.9	37



#	ARTICLE	IF	CITATIONS
109	Human Biomonitoring Data from Mercury Exposed Miners in Six Artisanal Small-Scale Gold Mining Areas in Asia and Africa. <i>Minerals</i> (Basel, Switzerland), 2011, 1, 122-143.	0.8	36
110	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. <i>Genetics in Medicine</i> , 2018, 20, 132-141.	1.1	36
111	Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. <i>American Journal of Cardiology</i> , 2000, 85, 266-269.	0.7	35
112	Long-term safety of therapy stratification in patients with intermediate coronary lesions based on intracoronary pressure measurements. <i>American Journal of Cardiology</i> , 2002, 90, 1160-1164.	0.7	34
113	Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis. <i>European Journal of Cancer</i> , 2011, 47, 1633-1646.	1.3	34
114	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. <i>Clinical Infectious Diseases</i> , 2014, 58, 1064-1071.	2.9	34
115	Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach. <i>Movement Disorders</i> , 2003, 18, S52-S62.	2.2	33
116	C-Reactive Protein Levels and Post-ICU Mortality in Nonsurgical Intensive Care Patients. <i>Chest</i> , 2010, 138, 856-862.	0.4	33
117	Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 34-50.	1.0	32
118	Epidemiology of status epilepticus in adults: Apples, pears, and oranges – A critical review. <i>Epilepsy and Behavior</i> , 2020, 103, 106720.	0.9	32
119	Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure. <i>Pharmacoeconomics</i> , 2011, 29, 753-769.	1.7	31
120	Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 790-797.	0.8	31
121	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
122	Determinants of willingness to pay for health services: a systematic review of contingent valuation studies. <i>European Journal of Health Economics</i> , 2022, 23, 1455-1482.	1.4	31
123	CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 159-165.	0.2	30
124	Effects of resistance training on respiratory function in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2013, 17, 217-226.	0.9	30
125	Ensuring Effective Prevention of Iodine Deficiency Disorders. <i>Thyroid</i> , 2016, 26, 189-196.	2.4	30
126	Economic burden of osteoporotic fractures in Austria. <i>Health Economics Review</i> , 2012, 2, 12.	0.8	29



#	ARTICLE	IF	CITATIONS
127	Case finding for hepatitis C in primary care: a cost utility analysis. <i>Family Practice</i> , 2006, 23, 393-406.	0.8	28
128	Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI. <i>Heart Lung and Circulation</i> , 2014, 23, 527-533.	0.2	27
129	Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1567-1578.	0.4	27
130	Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities—An Agent-Based Modeling Evaluation. <i>Vaccines</i> , 2021, 9, 434.	2.1	27
131	Comparison of pressure measurement, dobutamine contrast stress echocardiography and SPECT for the evaluation of intermediate coronary stenoses. The COMPRESS trial. <i>International Journal of Cardiovascular Interventions</i> , 2004, 6, 142-147.	0.5	26
132	Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 1026-1032.	2.9	26
133	Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response. <i>Pharmacoeconomics</i> , 2009, 27, 341-354.	1.7	26
134	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010, 11, 989-1002.	0.6	26
135	Vision and challenges of Evidence-Based Health Informatics: A case study of a CPOE meta-analysis. <i>International Journal of Medical Informatics</i> , 2010, 79, e83-e88.	1.6	26
136	Modelling the Cost Effectiveness of Treatments for Parkinson's Disease. <i>Pharmacoeconomics</i> , 2011, 29, 1025-1049.	1.7	26
137	When is enough evidence enough? Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2013, 107, 575-584.	0.7	26
138	TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 160-166.	0.2	26
139	Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review. <i>BMC Health Services Research</i> , 2019, 19, 737.	0.9	26
140	Prevention of Cervical Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 160-176.	0.8	26
141	Cost Effectiveness Analysis of Routine Use of Genotypic Antiretroviral Resistance Testing after Failure of Antiretroviral Treatment for HIV. <i>Antiviral Therapy</i> , 2004, 9, 27-36.	0.6	26
142	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. <i>Pharmacoeconomics</i> , 2004, 22, 321-341.	1.7	25
143	The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 21-33.	1.0	25
144	Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis. <i>European Journal of Haematology</i> , 2020, 104, 476-487.	1.1	25

#	ARTICLE	IF	CITATIONS
145	Evaluation of Contact-Tracing Policies against the Spread of SARS-CoV-2 in Austria: An Agent-Based Simulation. <i>Medical Decision Making</i> , 2021, 41, 1017-1032.	1.2	25
146	Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis. <i>BMC Public Health</i> , 2005, 5, 12.	1.2	24
147	Assessment and Characterization of Time-related Differences in Plaque Composition by Intravascular Ultrasoundâ€”derived Radiofrequency Analysis in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 302-309.	0.3	24
148	Systematic Assessment of Decision Models in Parkinson's Disease. <i>Value in Health</i> , 2004, 7, 610-626.	0.1	23
149	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. <i>European Urology</i> , 2017, 72, 899-907.	0.9	23
150	Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2475-2493.	0.7	23
151	Three-Year Clinical Follow-Up After Strontium-90/Yttrium-90 Beta-Irradiation for the Treatment of In-Stent Coronary Restenosis. <i>American Journal of Cardiology</i> , 2005, 96, 1399-1403.	0.7	22
152	Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: Serial angiographic and sonographic analysis. <i>American Heart Journal</i> , 2007, 153, 979.e1-979.e8.	1.2	21
153	Benefit, Risks and Cost-Effectiveness of Screening for Abdominal Aortic Aneurysm. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2010, 182, 573-580.	0.7	21
154	A biasâ€”adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. <i>Health Economics (United Kingdom)</i> , 2017, 26, 46-69.	0.8	21
155	The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria. <i>Value in Health</i> , 2017, 20, 1048-1057.	0.1	21
156	Do women with cancer have better survival as compared to men after adjusting for staging distribution?. <i>European Journal of Public Health</i> , 2011, 21, 387-391.	0.1	20
157	Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decisionâ€”Makers. <i>Health Economics (United Kingdom)</i> , 2015, 24, 481-490.	0.8	20
158	Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 13-19.	0.7	20
159	Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturationâ€”independent of absolute altitude?. <i>Sleep and Breathing</i> , 2016, 20, 435-442.	0.9	20
160	International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy. <i>Annals of Surgery</i> , 2021, 274, e966-e973.	2.1	20
161	Evolution of angiographic restenosis rate and late lumen loss after intracoronary beta radiation for In-Stent restenotic lesions. <i>American Journal of Cardiology</i> , 2004, 93, 836-842.	0.7	19
162	Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy. <i>European Radiology</i> , 2007, 17, 2384-2393.	2.3	19

#	ARTICLE	IF	CITATIONS
163	The Munich Score: A Clinical Index to Predict Survival in Ambulatory Patients With Chronic Heart Failure in the Era of New Medical Therapies. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 222-228.	0.3	19
164	Are survival rates for Tyrol published in the Eurocare studies biased?. <i>Acta Oncologica</i> , 2009, 48, 984-991.	0.8	19
165	Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2315-2325.	0.6	19
166	Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 333-351.	1.0	19
167	Why should we apply ABM for decision analysis for infectious diseases? An example for dengue interventions. <i>PLoS ONE</i> , 2019, 14, e0221564.	1.1	19
168	Prevention of Cervical Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 148-159.	0.8	19
169	Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries. <i>American Heart Journal</i> , 2000, 139, 632-637.	1.2	18
170	Magnetic Resonance Angiography in the Follow-up of Distal Lower-Extremity Bypass Surgery: Comparison with Duplex Ultrasound and Digital Subtraction Angiography. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 1269-1277.	0.2	18
171	Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon $\alpha$ -2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. <i>European Journal of Health Economics</i> , 2005, 6, 112-123.	1.4	18
172	Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 184-192.	0.2	18
173	Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 35.	1.0	18
174	Sex-Related Differences After a Single Bout of Maximal Eccentric Exercise in Response to Acute Effects: A Systematic Review and Meta-analysis. <i>Journal of Strength and Conditioning Research</i> , 2020, 34, 2697-2707.	1.0	18
175	Infants and mothers levels of mercury in breast milk, urine and hair, data from an artisanal and small-scale gold mining area in Kadoma / Zimbabwe. <i>Environmental Research</i> , 2020, 184, 109266.	3.7	18
176	Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. <i>European Journal of Health Economics</i> , 2021, 22, 1311-1344.	1.4	18
177	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, S4-S10.	0.9	17
178	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012, 13, 1405-1417.	0.6	17
179	Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review. <i>Epidemiology and Infection</i> , 2015, 143, 1791-1802.	1.0	17
180	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <i>BMJ Open</i> , 2020, 10, e036102.	0.8	17

#	ARTICLE	IF	CITATIONS
181	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1754-1759.	2.9	17
182	Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss's Error Propagation, an Alternative to Established Methods. <i>Medical Decision Making</i> , 2010, 30, 304-313.	1.2	16
183	Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 30-39.	0.2	16
184	Principles for planning and conducting comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 431-440.	0.6	16
185	Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. <i>Leukemia Research and Treatment</i> , 2015, 2015, 1-12.	2.0	16
186	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1311-1321.	2.2	16
187	Sirolimus-eluting stent implantation and $\hat{\text{I}}^2$ -irradiation for the treatment of in-stent restenotic lesions: Comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. <i>American Heart Journal</i> , 2005, 150, 351-357.	1.2	15
188	Tutorial in Medical Decision Modeling Incorporating Waiting Lines and Queues Using Discrete Event Simulation. <i>Value in Health</i> , 2010, 13, 501-506.	0.1	15
189	How Do We Improve the Impact of Iodine Deficiency Disorders Prevention in Europe and Beyond?. <i>European Thyroid Journal</i> , 2018, 7, 193-200.	1.2	15
190	Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. <i>PLoS ONE</i> , 2016, 11, e0147381.	1.1	15
191	Cabergoline versus levodopa monotherapy: A decision analysis. <i>Movement Disorders</i> , 2003, 18, 898-905.	2.2	14
192	The validation of fractional flow reserve in patients with coronary multivessel disease: a comparison with SPECT and contrast-enhanced dobutamine stress echocardiography. <i>Clinical Research in Cardiology</i> , 2005, 94, 321-327.	1.2	14
193	Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck. <i>Urologia Internationalis</i> , 2015, 94, 419-427.	0.6	14
194	Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. <i>BMC Cancer</i> , 2017, 17, 685.	1.1	14
195	On the role of data, statistics and decisions in a pandemic. <i>AStA Advances in Statistical Analysis</i> , 2022, 106, 349-382.	0.4	14
196	Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients. <i>Clinical Research in Cardiology</i> , 2010, 99, 83-91.	1.5	13
197	Introduction of organised mammography screening in Tyrol: results following first year of complete rollout. <i>BMC Public Health</i> , 2011, 11, 673.	1.2	13
198	Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. <i>Clinical Research in Cardiology</i> , 2015, 104, 304-309.	1.5	13

#	ARTICLE	IF	CITATIONS
199	Mediator Effect of Balance Problems on Association Between Grip Strength and Falls in Older Adults: Results From the KORA-Age Study. <i>Gerontology and Geriatric Medicine</i> , 2018, 4, 233372141876012.	0.8	13
200	Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. <i>BMC Gastroenterology</i> , 2019, 19, 209.	0.8	13
201	Reducing overtreatment associated with overdiagnosis in cervical cancer screening – A model-based benefit-harm analysis for Austria. <i>International Journal of Cancer</i> , 2020, 147, 1131-1142.	2.3	13
202	A systematic review of ethical and legal issues in elder care. <i>Nursing Ethics</i> , 2021, 28, 895-910.	1.8	13
203	PREDICTORS OF REDUCED CORONARY FLOW RESERVE IN HEART TRANSPLANT RECIPIENTS WITHOUT ANGIOGRAPHICALLY SIGNIFICANT CORONARY ARTERY DISEASE. <i>Transplantation</i> , 1999, 68, 1477-1481.	0.5	13
204	IVUS analysis of the acute and long-term stent result using motorized pullback: Intraobserver and interobserver variability. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 245-250.	0.7	12
205	Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention – does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 152.	1.5	12
206	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	1.2	12
207	Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. <i>BMC Medical Research Methodology</i> , 2019, 19, 69.	1.4	12
208	Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. <i>Journal of Medical Economics</i> , 2020, 23, 1061-1071.	1.0	12
209	Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. <i>GMS Health Technology Assessment</i> , 2010, 6, Doc05.	2.2	12
210	Comparison of volumetric intravascular ultrasound analysis of acute results and underlying mechanisms from cutting balloon and conventional balloon angioplasty for the treatment of coronary in-stent restenotic lesions. <i>American Journal of Cardiology</i> , 2002, 90, 539-542.	0.7	11
211	Safety of FFR-based treatment strategies: the Munich experience. <i>Clinical Research in Cardiology</i> , 2002, 91, 115-119.	1.2	11
212	A randomized comparison of 4 doses of intracoronary adenosine in the assessment of fractional flow reserve. <i>Clinical Research in Cardiology</i> , 2003, 92, 627-632.	1.2	11
213	Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening. <i>BMC Public Health</i> , 2010, 10, 86.	1.2	11
214	Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 164-178.	2.0	11
215	Status epilepticus admissions during the COVID-19 pandemic in Salzburg – A population-based study. <i>Epilepsia</i> , 2020, 61, e198-e203.	2.6	11
216	Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). <i>BMJ Open</i> , 2022, 12, e053246.	0.8	11

#	ARTICLE	IF	CITATIONS
217	Fractional flow reserve predicts major adverse cardiac events after coronary stent implantation. <i>Clinical Research in Cardiology</i> , 2002, 91, 132-136.	1.2	10
218	Comparison of acute and long-term results and underlying mechanisms from sirolimus-eluting stent implantation for the treatment of in-stent restenosis and recurrent in-stent restenosis in patients in whom intracoronary radiation failed as assessed by intravascular ultrasound. <i>American Journal of Cardiology</i> , 2004, 94, 917-921.	0.7	10
219	Health and environmental training in mercury-contaminated areas. <i>International Journal of Environment and Health</i> , 2007, 1, 621.	0.3	10
220	An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System. <i>Value in Health Regional Issues</i> , 2012, 1, 129-135.	0.5	10
221	Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. <i>SpringerPlus</i> , 2015, 4, 752.	1.2	10
222	Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria. <i>Breast</i> , 2017, 33, 178-182.	0.9	10
223	Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
224	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. <i>Cancer Prevention Research</i> , 2020, 13, 429-442.	0.7	10
225	The German Coronary Artery Disease Risk Screening Model: Development, Validation, and Application of a Decision-Analytic Model for Coronary Artery Disease Prevention with Statins. <i>Medical Decision Making</i> , 2009, 29, 619-633.	1.2	9
226	Applicability of two mobile analysers for mercury in urine in small-scale gold mining areas. <i>International Journal of Hygiene and Environmental Health</i> , 2011, 215, 64-67.	2.1	9
227	Introduction of organised mammography screening in tyrol: results of a one-year pilot phase. <i>BMC Public Health</i> , 2011, 11, 91.	1.2	9
228	USING EXPERT OPINION IN HEALTH TECHNOLOGY ASSESSMENT: A GUIDELINE REVIEW. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 131-139.	0.2	9
229	Recommendations for primary studies evaluating therapeutic medical devices were identified and systematically reported through reviewing existing guidance. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 46-58.	2.4	9
230	Ten recommendations for assessing the comparative effectiveness of therapeutic medical devices: a targeted review and adaptation. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 97-113.	2.4	9
231	Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1013-1025.	0.6	9
232	Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer – A Systematic Review. <i>Cancers</i> , 2020, 12, 1874.	1.7	9
233	Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. <i>Antiviral Therapy</i> , 2004, 9, 27-36.	0.6	9
234	The role of decision-analytic models in the prevention, diagnosis and treatment of coronary heart disease. <i>Clinical Research in Cardiology</i> , 2002, 91, 144-151.	1.2	8



#	ARTICLE	IF	CITATIONS
235	IQWiG methods â€“ a response to two critiques. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1137-1138.	0.8	8
236	Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 103-115.	1.0	8
237	The ONCOTYROL Prostate Cancer Outcome and Policy Model. <i>Medical Decision Making</i> , 2015, 35, 758-772.	1.2	8
238	Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview. <i>Thyroid</i> , 2020, 30, 746-758.	2.4	8
239	Benefits and Harms of a Prevention Program for Iodine Deficiency Disorders: Predictions of the Decision-Analytic EUthyroid Model. <i>Thyroid</i> , 2021, 31, 494-508.	2.4	8
240	Economic evaluation of newborn hearing screening: modelling costs and outcomes. <i>GMS German Medical Science</i> , 2003, 1, Doc09.	2.7	8
241	Discrepancy between morphologic and functional criteria of optimal stent deployment using intravascular ultrasound and pressure derived myocardial fractional flow reserve. <i>International Journal of Cardiovascular Interventions</i> , 2005, 7, 101-107.	0.5	7
242	Oncotyrol â€“ Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2015, 109, 330-340.	0.7	7
243	Costâ€Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Earlyâ€Stage Nonâ€Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 196-204.	1.9	7
244	Development of a novel prognostic score for breast cancer patients using mRNA expression of <i>CHAC1</i> . <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 563-574.	0.6	7
245	Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. <i>European Journal of Health Economics</i> , 2018, 19, 1229-1242.	1.4	7
246	Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. <i>PLoS ONE</i> , 2018, 13, e0204643.	1.1	7
247	RE: â€œEFFECT ESTIMATES IN RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES: COMPARING APPLES WITH APPLESâ€ American Journal of Epidemiology, 2020, 189, 77-78.	1.6	7
248	Costâ€Effectiveness analysis of superabsorbent wound dressings in patients with moderateâ€toâ€highly exuding leg ulcers in Germany. <i>International Wound Journal</i> , 2022, 19, 447-459.	1.3	7
249	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. <i>Annals of Hematology</i> , 2021, 100, 2921-2932.	0.8	7
250	Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective. <i>International Journal of Stroke</i> , 2023, 18, 416-425.	2.9	7
251	Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 109-117.	0.8	6
252	Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. <i>Medical Decision Making</i> , 2016, 36, 375-390.	1.2	6



#	ARTICLE	IF	CITATIONS
253	Budget Impact Analysis of Cancer Screening: A Methodological Review. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 493-511.	1.0	6
254	Effects of Motorcycle Noise on Annoyance—A Cross-Sectional Study in the Alps. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1580.	1.2	6
255	Barriers Against Prevention Programs for Iodine Deficiency Disorders in Europe: A Delphi Study. <i>Thyroid</i> , 2021, 31, 649-657.	2.4	6
256	Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. <i>American Journal of Cardiology</i> , 2021, 147, 61-69.	0.7	6
257	Non-mass Enhancement in Breast MRI: Characterization with BI-RADS Descriptors and ADC Values. <i>SciMedicine Journal</i> , 2021, 3, 77-87.	1.5	6
258	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. <i>Blood Advances</i> , 2021, , .	2.5	6
259	Response from the authors of “Key principles for the improved conduct of health technology assessments for resource allocation decisions” • <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 367-368.	0.2	5
260	Markov Processes for the Prediction of Aircraft Noise Effects on Sleep. <i>Medical Decision Making</i> , 2010, 30, 275-289.	1.2	5
261	OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. <i>Digestive and Liver Disease</i> , 2011, 43, S70.	0.4	5
262	Indirect treatment comparison of bevacizumab + interferon- $\alpha$ -2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 19.	0.7	5
263	Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 457-463.	2.2	5
264	Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2014, 17, 99-110.	1.0	5
265	Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 23.	0.6	5
266	Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR. <i>BMC Gastroenterology</i> , 2020, 20, 131.	0.8	5
267	The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany. <i>Endocrine Connections</i> , 2021, 10, 1-12.	0.8	5
268	Antiviral treatment initiation costs in chronic hepatitis C. <i>Gut</i> , 2005, 54, 172-3.	6.1	5
269	Presentation and medical management of peripheral arterial disease in general practice: rationale, aims, design and baseline results of the PACE-PAD Study. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2009, 17, 127-135.	0.8	4
270	Deterministic Sensitivity Analysis for First-Order Monte Carlo Simulations: A Technical Note. <i>Value in Health</i> , 2009, 12, 96-97.	0.1	4

#	ARTICLE	IF	CITATIONS
271	Effect of guideline orientation on the outcomes of peripheral arterial disease in primary care. <i>Current Medical Research and Opinion</i> , 2011, 27, 1183-1190.	0.9	4
272	Medical decision analysis for first-line therapy of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1758-1767.	0.6	4
273	Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. <i>European Journal of Public Health</i> , 2016, 26, 498-505.	0.1	4
274	&lt;p&gt;The Optimizing-Risk-Communication (OptRisk) randomized trial &ndash; impact of decision-aid-based consultation on adherence and perception of cardiovascular risk&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 441-452.	0.8	4
275	Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc06.	2.2	4
276	Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions. <i>Atherosclerosis</i> , 2022, 355, 15-29.	0.4	4
277	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2011, 27, 2193-2201.	0.9	3
278	Health state utilities among contemporary prostate cancer patients on active surveillance. <i>Translational Andrology and Urology</i> , 2018, 7, 197-202.	0.6	3
279	Systematic assessment of decision-analytic models evaluating diagnostic tests for acute myocardial infarction based on cardiac troponin assays. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 619-640.	0.7	3
280	Individual health services. <i>GMS Health Technology Assessment</i> , 2011, 7, Doc05.	2.2	3
281	Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system. <i>GMS Health Technology Assessment</i> , 2005, 1, Doc03.	2.2	3
282	Influence of tumor necrosis factor $\hat{\pm}$ in rheumatoid arthritis. <i>GMS Health Technology Assessment</i> , 2005, 1, Doc12.	2.2	3
283	Screening of the hearing of newborns - Update. <i>GMS Health Technology Assessment</i> , 2006, 2, Doc20.	2.2	3
284	Safety and mechanisms of intracoronary manual stepping brachytherapy as gained from serial angiographic and intravascular ultrasound studies. <i>American Journal of Cardiology</i> , 2002, 90, 1385-1388.	0.7	2
285	Cabergoline versus levodopa monotherapy. <i>Movement Disorders</i> , 2004, 19, 733-734.	2.2	2
286	Reply: Cabergoline versus levodopa therapy. <i>Movement Disorders</i> , 2004, 19, 734-736.	2.2	2
287	HT1 A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES. <i>Value in Health</i> , 2008, 11, A337-A338.	0.1	2
288	Coronary plaque dimensions and composition by intravascular ultrasound radio frequency lesion segment analysis in stable and unstable angina patients. <i>Coronary Artery Disease</i> , 2009, 20, 309-316.	0.3	2

#	ARTICLE	IF	CITATIONS
289	Evaluating HTA principles. International Journal of Technology Assessment in Health Care, 2010, 26, 429-430.	0.2	2
290	Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 572-574.	8.2	2
291	Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. European Journal of Health Economics, 2013, 14, 1035-1048.	1.4	2
292	ISPOR-SMDM Task Force's Recommendations for Good Modeling Practices"Reply to Letter to the Editor by Corro Ramos. Value in Health, 2013, 16, 1108.	0.1	2
293	885 IMMEDIATE vs. DELAYED TREATMENT IN GENOTYPE 4-HCV INFECTED PATIENTS IN A LIMITED RESOURCES COUNTRY: A COST-EFFECTIVENESS ANALYSIS IN EGYPT (ANRS 12215). Journal of Hepatology, 2013, 58, S364.	1.8	2
294	The Use Of Administrative Data To Determine Prevalence And Incidence Of Copd: A Systematic Review. Value in Health, 2016, 19, A368-A369.	0.1	2
295	Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness. Medical Decision Making, 2019, 39, 509-522.	1.2	2
296	Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value in Health Regional Issues, 2019, 20, 95-102.	0.5	2
297	Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis. Journal of Clinical Medicine, 2021, 10, 807.	1.0	2
298	Costs of sequential multiple myeloma treatment for elderly transplant-ineligible patients in the Serbian health care system. Medicinski Pregled, 2019, 72, 88-97.	0.1	2
299	Orchiectomy versus medical therapy with LH-RH analogues for the treatment of advanced prostatic carcinoma. GMS Health Technology Assessment, 2006, 2, Doc13.	2.2	2
300	An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply. PLoS ONE, 2022, 17, e0265957.	1.1	2
301	PCN2 COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS. Value in Health, 2002, 5, 536-537.	0.1	1
302	VV6 TRANSFORMING THE UNIFIED PARKINSON'S DISEASE RATING SCALE INTO A UTILITY SCALE. Value in Health, 2003, 6, 611-612.	0.1	1
303	The influence of analytic time horizon and treatment management algorithms on the cost of peginterferon alfa-2b plus ribavirin therapy for chronic hepatitis C. Journal of Hepatology, 2003, 38, 173.	1.8	1
304	Reply to the letter to the editor by J.G. D'Área "Health hazard for infants: Breast-milk mercury or non-breastfeeding? A dilemma for mothers exposed to mercury vapours". International Journal of Hygiene and Environmental Health, 2009, 212, 235-237.	2.1	1
305	Die Bewertung der Kosteneffektivität von Impfungen unter Berücksichtigung von Public Health Aspekten. Public Health Forum, 2009, 17, 9-11.	0.1	1
306	CN4 HPV-BASED PRIMARY CERVICAL CANCER SCREENING IN GERMANY. COST-EFFECTIVENESS RESULTS FROM A DECISION-ANALYTIC MODELING STUDY. Value in Health, 2010, 13, A239.	0.1	1

#	ARTICLE	IF	CITATIONS
307	Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 345-352.	1.2	1
308	Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting. International Journal of Public Health, 2014, 59, 175-187.	1.0	1
309	TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A META-ANALYSIS AND INDIRECT TREATMENT COMPARISON. Value in Health, 2015, 18, A432.	0.1	1
310	Cost-Effectiveness of Different Cervical Cancer Primary Screening Using Cytology, HPV Or P16/KI-67 Testing Alone Or in Combinations for The Austrian Health Care Context. Value in Health, 2016, 19, A694.	0.1	1
311	Cost utility of fractional flow reserve-guided percutaneous coronary intervention in multivessel coronary artery disease in Brazil. International Journal for Quality in Health Care, 2018, 31, 676-681.	0.9	1
312	Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants. MDM Policy and Practice, 2018, 3, 238146831775192.	0.5	1
313	New Perspective for Soft Tissue Closure in Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Barbed Sutures. Journal of Clinical Medicine, 2021, 10, 1677.	1.0	1
314	Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia. Zdravstveno Varstvo, 2020, 59, 83-91.	0.6	1
315	Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment. GMS German Medical Science, 2003, 1, Doc07.	2.7	1
316	Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical. GMS Health Technology Assessment, 2007, 3, Doc08.	2.2	1
317	Impact of barotrauma on acute and late angiographic and clinical outcomes following angioplasty and beta-irradiation of coronary in-stent restenotic lesions. Journal of Invasive Cardiology, 2004, 16, 14-9.	0.4	1
318	UT4 PATIENT-DERIVED UTILITY ESTIMATES OF CHRONIC HEPATITIS C BASED ON EQ-5D AND RS SCORES. Value in Health, 2002, 5, 460-461.	0.1	0
319	Cost-effectiveness of peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Journal of Hepatology, 2002, 36, 129-130.	1.8	0
320	Does health-related quality of life reflect disease severity in chronic hepatitis C patients?. Journal of Hepatology, 2002, 36, 130.	1.8	0
321	HP2 THE IMPACT OF TREATMENT MANAGEMENT ALGORITHMS AND EVALUATED TIME HORIZON ON ANTIVIRAL TREATMENT COSTS IN CHRONIC HEPATITIS C. Value in Health, 2003, 6, 608-609.	0.1	0
322	PCV34 COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA: A DECISION ANALYSIS. Value in Health, 2003, 6, 655-656.	0.1	0
323	PHL3 COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT: A CROSS-NATIONAL ASSESSMENT. Value in Health, 2003, 6, 740.	0.1	0
324	PHL10 ASSESSING PATIENT PREFERENCES AND QUALITY-ADJUSTED LIFE YEARS (QALY) OF PROPHYLACTIC HAEMOPHILIA TREATMENT. Value in Health, 2003, 6, 743.	0.1	0

#	ARTICLE	IF	CITATIONS
325	PIN6 CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPESPECIFIC GUIDELINES. Value in Health, 2004, 7, 759-760.	0.1	0
326	PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASEâ€”A MULTIVARIATE ANALYSIS. Value in Health, 2004, 7, 793-794.	0.1	0
327	Application, Feasibility, and Efficacy of a Combined Intravascular Ultrasound and Stent Delivery System: Results from a Prospective Multicenter Trial. Journal of Interventional Cardiology, 2005, 18, 367-374.	0.5	0
328	MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS. Value in Health, 2005, 8, A17.	0.1	0
329	PGI17 ARTIFICIAL LIVER SUPPORT SYSTEMSâ€”A MEDICAL AND HEALTH ECONOMIC HTA-REPORT. Value in Health, 2005, 8, A123.	0.1	0
330	PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENINGâ€”A SYSTEMATIC REVIEW. Value in Health, 2008, 11, A437-A438.	0.1	0
331	Decision-analytic models for breast cancer: Do currently published models meet the requirements of personalized medicine?. , 2008, , .		0
332	PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC). Value in Health, 2009, 12, A258.	0.1	0
333	Outcomes of medical management of peripheral arterial disease in general practice: follow-up results of the PACE-PAD Study. Zeitschrift Fur Gesundheitswissenschaften, 2010, 18, 523-532.	0.8	0
334	PCN161 DECISION-ANALYTIC MODELING IN CHRONIC MYELOID LEUKEMIAâ€”A SYSTEMATIC OVERVIEW. Value in Health, 2010, 13, A281-A282.	0.1	0
335	PHP124 Personalized Decision Making in Cancer Medicine? Systematic Overview of HTA Procedures and Specific Approaches in Ten Countries Across Four Continents. Value in Health, 2011, 14, A355-A356.	0.1	0
336	Personalisierte Krebstherapie. PharmacoEconomics - German Research Articles, 2012, 10, 87-104.	0.1	0
337	PIN90 Towards Best Practices for Handling Uncertainties in Health Technology Assessments for HPV Vaccination to Better Inform Decision Making. Value in Health, 2012, 15, A401-A402.	0.1	0
338	PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy. Value in Health, 2012, 15, A209.	0.1	0
339	Framework for Evidence Assessment Based on Grade and Application to HPV Vaccination in Males in the European Health Care Context. Value in Health, 2013, 16, A327.	0.1	0
340	To stop or not to stop: a value of information view. European Journal of Epidemiology, 2018, 33, 785-787.	2.5	0
341	Comparative Effectiveness Analysis Using Real World Evidence (RWE) and Applying a Causal Marginal Structural Model: the Case of Second-Line Treatment in Patients with Ovarian Cancer. Value in Health, 2018, 21, S18.	0.1	0
342	GesundheitsÃ¶konomische Bewertungen. , 2010, , 557-573.		0

#	ARTICLE	IF	CITATIONS
343	Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma. Blood, 2013, 122, 2991-2991.	0.6	0
344	Public-Health-Studium: Bayerischer Public Health L�rwe 1998. Public Health Forum, 1998, 6, 22-22.	0.1	0
345	A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.. Journal of Clinical Oncology, 2014, 32, e18509-e18509.	0.8	0
346	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes â€” a Delphi Survey from the European-MDS Registry. Blood, 2018, 132, 2295-2295.	0.6	0
347	Pharmacoeconomics. , 2020, , 1-135.		0
348	Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. Medical Decision Making, 2021, , 0272989X21110262.	1.2	0
349	Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity. GMS Health Technology Assessment, 2008, 4, Doc03.	2.2	0
350	Measurement of fractional flow reserve to guide decisions for percutaneous coronary intervention. GMS Health Technology Assessment, 2008, 4, Doc07.	2.2	0
351	Extracorporeal hemodialysis with acute or decompensated chronic liver failure. GMS Health Technology Assessment, 2006, 2, Doc08.	2.2	0